Trial Profile

Phase I/II trial of IMO-2125 in combination with ipilimumab and nivolumab in patients with multiple tumor types including non-small cell lung cancer, melanoma, squamous cell carcinoma of the head and neck and urothelial carcinoma.

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 09 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Tilsotolimod (Primary)
Indications Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Squamous cell cancer; Urogenital cancer
Focus Adverse reactions; Therapeutic Use

17 Jan 2023 According to an Aceragen media release, Idera Pharmaceuticals has changed its name to Aceragen
06 Nov 2018 According to the Idera Pharmaceuticals media release, The principal investigator initiating this trial is Aurelien Marabelle, MD, PhD, Clinical Director of the Cancer Immunotherapy Program at Institut Gustave Roussy, Villejuif, France.
23 Apr 2018 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com